NewAmsterdam Pharma NAMS
NASDAQ NAMS
$23.20 -0.96 (-3.97%)
At close: Oct 2, 2026 · 4:00 PM EDT

NewAmsterdam Pharma (NAMS) Non Operating Investment Income (2025)

Updated

NewAmsterdam Pharma (NAMS) reported Non Operating Investment Income of -$1,000 for Q3 2025.

Analysis

NewAmsterdam Pharma (NAMS) Non Operating Investment Income (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Op. Investment Inc. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -
10 NewAmsterdam Pharma 2.73 Bn 2.73 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -1,000.00
API Access

NewAmsterdam Pharma Non Operating Investment Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=NAMS&period=max&api_key=YOUR_API_KEY